Compare MSGE & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | PBLS |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2023 | 2026 |
| Metric | MSGE | PBLS |
|---|---|---|
| Price | $77.58 | $31.94 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | 388.3K | ★ 451.4K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $942,734,000.00 | N/A |
| Revenue This Year | $10.53 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $48.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.31 | $25.56 |
| 52 Week High | $82.79 | $33.65 |
| Indicator | MSGE | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 58.76 |
| Support Level | $72.96 | $26.83 |
| Resistance Level | $82.79 | $32.15 |
| Average True Range (ATR) | 1.84 | 2.57 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 82.52 | 74.20 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.